Form 4 for CLDI Calidi Biotherapeutics, Inc.
Accepted 2023-09-14 00:00:00 ET · period of report 2023-09-12 · accession 0001393825-23-000222 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-09-14 | 2023-09-12 | CLDI | Hudson Bay Capital Management LP | 10% | J - Other | $10.49 | -500.0K | 0 | -100% | -$5.25M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock, par value $0.0001 per share | 2023-09-12 | J | D | 500,000 | $10.49 | 0 | I See footnote | — | — | (F2) Reflects the Reporting Persons' best estimate of the redemption price based on the Issuer's disclosure in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 21, 2023. The Reporting Persons will file and amendment to this Form 4 to the extent the actual redemption price differs in any material respect from the price reported in column (4). (F3) The securities are held by HB Strategies LLC (the "Fund"). Hudson Bay Capital Management LP (the "Investment Manager") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein. |